



# Heart Rate Variability in Adults with Sickle Cell Anemia During a Multitasking Field Test

Rafael Alexandre de Oliveira Deucher<sup>1</sup>, Arthur de Sá Ferreira <sup>1</sup>, Leila Paula Alves da Silva Nascimento<sup>1</sup>, Mariana Soares da Cal<sup>2</sup>, Jannis Vasileios Papathanasiou <sup>3,4</sup> and Agnaldo José Lopes <sup>1,2,\*</sup>

<sup>1</sup>Rehabilitation Sciences Post-Graduate Program, Augusto Motta University Center (UNISUAM), Rio de Janeiro, Brazil

<sup>2</sup>School of Medical Sciences, State University of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil

<sup>3</sup>Department of Medical Imaging, Allergology and Physiotherapy, Faculty of Dental Medicine, Medical University of Plovdiv, Bulgaria

<sup>4</sup>Department of Kinesitherapy, Faculty of Public Health, Medical University of Sofia, Bulgaria

\*Corresponding author: Rehabilitation Sciences Post-Graduate Program, Augusto Motta University Center (UNISUAM), Rua Dona Isabel, No. 94, Bonsucesso, Postal Code: 21032-060, Rio de Janeiro, Brazil. Email: agnaldolopes.uerj@gmail.com

Received 2020 August 19; Revised 2021 April 05; Accepted 2021 May 20.

## Abstract

**Background:** The integrity of the autonomic nervous system (ANS) is essential for keeping physiological processes stable, even under stress. Since there is growing interest in heart rate variability (HRV) analysis for the noninvasive assessment of the ANS in sickle cell anemia (SCA) patients, we studied the behavior of the ANS in the presence of a stressor that simulates daily-life multitasking, the Glittre ADL test (GA-T).

**Objectives:** To evaluate the involvement of the ANS using HRV in adults with SCA during the GA-T and to quantify the strength of the correlation of HRV with lung and muscle functions.

**Methods:** In this cross-sectional study, 16 adults with SCA and 12 healthy controls without sickle cell disease underwent HRV assessment during the GA-T, pulmonary function tests (spirometry, diffusing capacity for carbon monoxide (DLCO), and respiratory muscle testing). Peripheral muscle function [handgrip strength (HGS) and quadriceps strength (QS)] were also measured.

**Results:** Compared to the healthy controls, adults with SCA showed lower HRV, with worse parasympathetic modulation due to reductions in the following indices: the root-mean-square difference of successive normal iRRs (iRR) (RMSSD); the percentage of pairs of consecutive iRRs whose difference is > 50 m (pNN50); the high-frequency component of heart rate variability (HF); and the standard deviation of instantaneous beat-to-beat variability (SD1) ( $P < 0.001$  for all). Compared to healthy controls, individuals with SCA showed greater sympathovagal imbalance (higher ratio between low-frequency and HF components) and lower complexity of the ANS (lower approximate entropy). The GA-T time was correlated with parasympathetic activity indices: RMSSD ( $r_s = -0.650$ ,  $P < 0.01$ ); pNN50 ( $r_s = -0.932$ ,  $P < 0.0001$ ), HF ( $r_s = -0.579$ ,  $P < 0.01$ ), and SD1 ( $r_s = -0.814$ ,  $P < 0.0001$ ). Correlations between parasympathetic activity indices and DLCO, HGS, and QS measures were also significant.

**Conclusions:** Adults with SCA have low HRV, with low parasympathetic activity, sympathovagal imbalance, and abnormal ANS complexity. In addition, lower HRV is associated with longer GA-T time, greater impairment of pulmonary diffusion, and greater muscle strength dysfunction.

**Keywords:** Sickle Cell Anemia, Heart Rate Variability, Functional Capacity

## 1. Background

Sickle cell disease (SCD) is a hereditary condition with high prevalence and high morbidity and mortality worldwide (1). SCD encompasses a variety of genotypes characterized by the presence of the hemoglobin S gene that can occur in heterozygosity with other abnormal hemoglobin genes. In the homozygous form, the disease is called sickle cell anemia (SCA) and is characterized by a clinically more severe phenotype than the heterozygous form (2). In in-

dividuals with SCA, changes in blood rheology, chronic inflammatory processes, and vascular damage play a key role in the occurrence of disease complications (3). From the pathophysiological point of view, this chronic hemolytic condition involves recurrent episodes of inflammation, oxidative stress, and vascular occlusion, causing acute manifestations, especially the vaso-occlusive crisis (VOC), which can also lead to chronic multiple-organ dysfunction, including of the heart (3).

Cardiovascular disease (CVD) is increasingly recognized as a major contributor to premature death in people with SCA (4). The cardiovascular abnormalities in these individuals include cardiomegaly, hyperdynamic precordium, systolic murmurs, and biventricular hypertrophy (5, 6). In addition, individuals with SCA experience VOCs that may occasionally be associated with abnormalities in the cardiac conduction system and myocardial infarction (5). Curiously, sudden death events with no detectable cause at autopsy sums up to 40% of all deaths in adults with SCA (6). However, there is increasing evidence of an abnormal function of the autonomic nervous system (ANS) in SCA, which may lead to an increased risk of sudden death. In addition, ANS dysfunction in SCA seems to be clearly associated with a reduction in the ankle-brachial systolic blood pressure index, erectile dysfunction, syncope, leg ulcers, and acute chest syndrome (ACS) (7).

The ANS imbalance caused by low parasympathetic activity at rest and impaired ANS reactivity during different challenges -both leading to autonomic imbalances- have been reported in individuals with SCA, with the degree of change reflecting the clinical severity (8, 9). The ANS plays an important role in blood flow regulation because the blood vessels, especially the arterioles, are innervated by nerves of the sympathetic nervous system (SNS) (3). Therefore, abnormal autonomic control of peripheral vascular resistance may predispose individuals with SCA to prolonged vasoconstriction in response to stress stimuli and exacerbate ANS changes (4).

The Glittre ADL test (GA-T)-which is an important stress stimulus- was developed to meet the need for a broader and more representative objective evaluation of functionality by involving tasks that simulate activities of daily living (ADLs), including arm activities performed without support, walking, going up stairs, reaching, handgrip and carrying weight (10, 11). Since there is growing interest in the study of heart rate variability (HRV) as it comprises a noninvasive method for assessing the autonomic nerve activity in individuals with SCA, we decided to evaluate HRV during multitasking in the GA-T, which encompasses both upper- and lower-limb activities.

## 2. Objectives

To evaluate the involvement of the ANS using HRV in adults with SCA during GA-T and to quantify the strength of the correlation of HRV variables with pulmonary and peripheral muscle functions.

## 3. Methods

### 3.1. Participants

This cross-sectional study was performed in adults with SCA aged  $\geq 18$  years who were regularly monitored at Pedro Ernesto University Hospital of the State University of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil. Inclusion criteria for patients comprised a steady state of the disease (i.e. without blood transfusion in the past 3 months) and no occurrence of infection, ACS, or VOC within  $> 1$  month prior to study enrollment (9). The following exclusion criteria were used: known acute or chronic diseases, including CVD, stroke, kidney disease, liver disease, asthma, and diabetes; significant sickle cell symptoms and/or VOC less than 4 weeks from the beginning of the study; use of cardioactive drugs such as  $\beta$ -blockers, glucosides, and antiarrhythmic agents, or other drugs known to affect ANS functions (e.g. antidepressants, diuretics, antihistamines, aspirin); history of surgery on the upper or lower limbs; and inability to walk. We also evaluated 12 healthy controls without sickle cell disease aged  $\geq 18$  years. This group was recruited at the Augusto Motta University Center, Rio de Janeiro, Brazil and was composed of individuals able to walk who had no previous history of cardiopulmonary or musculoskeletal disease.

The Research Ethics Committee of the State University of Rio de Janeiro approved this study protocol (No. 1.718.917/2016) and all participants signed a written informed consent form.

### 3.2. Pulmonary Function Testing (PFT)

PFT -spirometry, diffusing capacity for carbon monoxide (DLCO), and respiratory muscle testing (RMT)-were performed on an HDpft 3000 device (nSpire Health, Inc., Longmont, CO, USA) following the standardization and interpretation previously established (12). DLCO was evaluated by the single breath-hold technique and was summarized as the mean of two measures.

The units for the PFTs parameters (absolute values) were as follows: forced vital capacity, L; DLco, mL CO/min/mmHg; maximal inspiratory pressure, cm H<sub>2</sub>O; and maximal expiratory pressure, cm H<sub>2</sub>O. However, as recommended by the American Thoracic Society and European Respiratory Society, the interpretation of PFTs requires comparison with predicted values because pulmonary function is influenced by anthropometric (e.g. sex, age and height) and ethnic characteristics to predict the normal pulmonary function (13, 14). The comparison of the absolute values in relation to the predicted values for pulmonary function is intended to separate the effects

of pathological conditions from normal variability among healthy subjects. Thus, the predicted values of each participant for spirometry, DLCO, and RMT in the present study were calculated using national equations because of the biotype and ethnic characteristics of our population (15-17).

### 3.3. Peripheral Muscle Function (PMF)

The PMF was evaluated through handgrip strength (HGS) and quadriceps strength (QS). HGS was measured by a maximal isometric strength test with the SH5001 device (Saehan Corporation, Korea) in the dominant upper limb. The participants were positioned according to standard recommendations (18), with their elbow flexed at 90°, the forearm half-pronated, and the wrist in a neutral position. HGS was summarized as the highest value of three attempts with a 60-s rest time. The QS was evaluated with a tension dynamometer (sensor capacity = 200 kg, E-elastic 5.0, E-sporte SE, Brazil). The range of motion within 90° during the test was determined, starting at 90° flexion at the knee. The maximum force was assessed in the dominant leg after a 5-s sustained isometric contraction. QS was summarized as the highest value from three attempts with a 1-min intervals (19).

### 3.4. GA-T

The GA-T was given as previously described (10, 11). The GA-T is a test that comprises multiple tasks that simulate ADLs, including lifting a chair, walking along a path interposed at its midpoint by a staircase, removing boxes from a shelf and placing those boxes on another shelf; and placing the boxes on the floor and then putting them back on a shelf (Figure 1). The protocol was performed twice at an interval of 30 min, and the data for the shorter GA-T were taken for analysis and expressed as total time to complete the multitasks (10, 11).

### 3.5. Autonomic Nervous System Activity

The RR interval (iRR) signals obtained from the electrical cardiac activity and captured by the telemetric cardiac monitor V800 (Polar OY, Finland) were exported to Kubios software (Kuopio, Finland) to calculate the HRV indices during the GA-T. The sampling frequency was 1,000 Hz, and any iRR with a difference > 20% from the previous interval was automatically filtered out by the program (20).

HRV in the time domain, frequency domain, and Poincaré plot non-linear analysis were performed as described by the Task Force recommendations (21-23). Time


domain analysis included the following variables: (1) mean iRR; (2) maximum heart rate (maximum HR); (3) standard deviation of all normal iRRs (SDNN), which shows the general ANS activity; (4) root-mean-square difference of successive normal iRRs (RMSSD), showing the parasympathetic nervous system (PNS) modulation; (5) percentage of pairs of consecutive iRRs whose difference is > 50 m (pNN50), which also shows PNS modulation; and (6) triangular interpolation of the iRR histogram (TINN), which shows the general ANS activity (21). The frequency domain measures were mainly total power (TP, 0.04 - 0.15 Hz), which shows the general ANS activity, and its low-frequency component [LF, (0.04 - 0.15 Hz)], which is predominant an indicator of SNS activity, and its high-frequency component [HF, (0.15 - 0.4 Hz)], which is an indicator of PNS activity. Last, the LF/HF ratio shows the sympathovagal balance, a high value indicating SNS dominance (22, 23). At the end, Poincaré plot non-linear measures were evaluated: standard deviation of instantaneous beat-to-beat variability (SD1), which describes short-term variability (shows PNS modulation); standard deviation of long-term continuous iRRs (SD2), which describes long-term variability (shows general ANS activity); the SD2/SD1 ratio; and approximate entropy (ApEn), which detects changes in a time series, indicating ANS complexity.

### 3.6. Statistical Analysis

The distribution of data was determined by the Shapiro-Wilk test. Data are summarized using mean  $\pm$  SD, median (interquartile range), or frequency (percentage). Between-group comparisons of demographic data, pulmonary function, PMF, GA-T time, and HRV were evaluated using independent samples t test or the Mann-Whitney test for numerical data and by Fisher's exact test for categorical data. The correlation between HRV, GA-T time, pulmonary function, and PMF variables were analyzed using the Spearman's correlation coefficient (rs). The significance level adopted was 5%. Data analysis was performed using SAS 6.11 software (SAS Institute, Inc., Cary, NC, USA).

## 4. Results

Twenty-three adults with SCA were eligible for the study; seven adults with SCA were excluded because they presented a VOC at less than 4 weeks before the study (n = 3); use of cardioactive drugs or drugs that could affect autonomic functions (n = 3); or inability to walk (n = 1). Thus, the sample evaluated consisted of 16 adults with SCA



**Figure 1.** In the Glittre ADL test, the participant carries a backpack on his back with a weight of 2.5 kg for women and 5 kg for men and walks a 10 m circuit. The participant, from the seated position, walks a course interposed in his half by a box with 2 steps to go up and 2 to go down. After going through the rest of the route, the participant is faced with a shelf containing 3 boxes of 1 kg each, located on the highest shelf, and must then move them, one at a time, to the lowest shelf and, later, up to the floor. Then, the boxes must be replaced on the lowest shelf and later on the highest shelf. Then, the participant comes back, taking the route in reverse. Immediately afterwards, he starts another lap, covering the same circuit, until he completes five laps.

(with a mean age of  $29.9 \pm 8$  years) and 12 healthy controls without sickle cell disease (with a mean age of  $30.5 \pm 7.2$  years). Compared to healthy controls, adults with SCA showed lower values of pulmonary function (including RMT), HGS, and QS. The demographic data, pulmonary function, and PMF of individuals with SCA and healthy controls are shown in [Table 1](#).

The median time to perform the GA-T tasks was 257 (198 - 368) s in adults with SCA, which was significantly higher than the time observed in the healthy controls. Regarding the HRV variables measured during the GA-T, adults with SCA showed values that differed from the healthy controls for all indices, except for the SD1/SD2 ratio. The most striking differences between the two groups were observed for the following variables: RMSSD, pNN50, HF, LF/HF ratio, SD1, and ApEn ( $P < 0.0001$  for all). The GA-T measures and HRV indexes during the GA-T are shown in [Table 2](#).

The correlation analysis between HRV variables, GA-T time, pulmonary function, and PMF are shown in [Table 3](#) and [Figure 2](#). The strongest correlations were between the PNS modulation indices (especially RMSSD, pNN50, and SD1) and the GA-T time, DLCO, maximal inspiratory pressure (PI<sub>max</sub>), HGS, and QS. Additionally, the GA-T time correlated significantly with DLCO ( $r_s = -0.673$ ,  $P = 0.004$ ), PI<sub>max</sub> ( $r_s = -0.755$ ,  $P = 0.0007$ ), HGS ( $r_s = -0.660$ ,  $P = 0.005$ ), and QS ( $r_s = -0.718$ ,  $P = 0.002$ ).

## 5. Discussion

The ANS regulates various physiological processes and its physiologic functioning is essential for maintaining stability, even in the presence of stressors. HRV, which is the variability in time and/or frequency of consecutive R waves of the heartbeat, has emerged as a noninvasive electrocardiographic marker of the influence of the activities of the SNS and PNS of the ANS on the sinoatrial node of the heart (24). Assuming the multitasking of the GA-T would be a strong stressor of the SNA in adults with SCA, we evaluated the phenotype of HRV in this population. Our main findings were that, compared to healthy controls, adults with SCA had a marked reduction in HRV during the performance of the GA-T, in regard to the activity of both the SNS and the PNS. This reduced HRV occurred especially at the expense of parasympathetic activity, sympathovagal balance, and abnormal ANS complexity. In these individuals, there was a relationship between a lower HRV (especially of the indices that reflect vagal modulation) and a longer GA-T time, worse pulmonary diffusion, and lower respiratory and peripheral muscle strength. In addition, a worse performance on the GA-T (i.e., a longer time to perform its multiple tasks) was associated with worse pulmonary diffusion and respiratory/peripheral muscle strength. To the best of our knowledge, this study is the first to explore the performance of the ANS during the GA-T in individuals with SCA.

In SCA, the PNS functions seem to be more impaired than the SNS functions (5), with the relative predominance of the action of the SNS promoting peripheral vasocon-

**Table 1.** Demographic, Pulmonary Function and Peripheral Muscle Function Data of Patients and Healthy Controls<sup>a</sup>

Variables	Sickle Cell Anemia Group (n = 16)	Control Healthy Group (n = 12)	P Value
<b>Demographic Data</b>			
Age, y	29.9 ± 8	30.5 ± 7.2	0.85
Sex, female/male	9/7	8/4	0.43
Weight, kg	63.8 ± 14.4	64.9 ± 10.4	0.82
Height, cm	164 ± 7	162 ± 5	0.43
BMI, kg/m <sup>2</sup>	23.6 ± 4.2	24.8 ± 3	0.40
<b>Pulmonary Function</b>			
FVC (% predicted)	75 (58 - 86)	96 (87 - 100)	0.0004
DLco (% predicted)	69 (57 - 98)	116 (103 - 118)	< 0.0001
PImax (% predicted)	49 (40 - 63)	101 (95 - 115)	< 0.0001
PEmax (% predicted)	48 (25 - 61)	94 (85 - 108)	< 0.0001
<b>Peripheral Muscle Function</b>			
HGS (kgf)	24 (17 - 36)	39 (33 - 46)	0.006
QS (kgf)	23 (14 - 31)	33 (30 - 36)	0.002

Abbreviations: BMI, body mass index; FVC, forced vital capacity; DLco, diffusing capacity for carbon monoxide; PImax, maximal inspiratory pressure, PEmax, maximal expiratory pressure; HGS, handgrip strength; QS, quadriceps strength.

<sup>a</sup> Values expressed as mean ± SD or median and interquartile interval values.

striction and reduction of local perfusion and, therefore, increasing the polymerization of hemoglobin S and the sickling of red blood cells (25). In the present study, when individuals with SCA were compared to healthy controls, we observed lower PNS and SNS activity, although there was a clear parasympathetic withdrawal, with significantly lower RMSSD, pNN50, HF, and SD1 (all with  $P < 0.0001$ ). In addition, we observed a sympathovagal imbalance represented by the high LF/HF ratio. In line with these findings, several studies have shown a persistent and sustained decrease in autonomic fluctuations in people with SCA, with a clear reduction in the PNS activity, both at rest and during exercise (3, 4, 8, 9, 25). Although the exact mechanism of cardiovascular autonomic dysfunction in SCA is not fully clear, many factors contribute to its pathophysiology, including fibromuscular dysplasia, damaged small vessel circulation, focal degeneration and apoptosis, procoagulant activity, abnormal coronary chemoreceptors, and increased oxidative stress (7). In SCA, long-term hypoxemia causes loss of cells in the ambiguous nucleus, which is a set of cells where several vagal efferent axons innervate the ganglionic plexuses on the dorsal surface of both atria (25).

HRV behaves as a complex, non-linear deterministic system with high variability that follows chaos theory and is modulated by the ANS (21). In fact, there is growing interest in evaluating the complexity of short-term cardiovascular control through HRV analysis. Non-linear analyses of

the HRV are based on its random and nonperiodic nature and the fact that the HRV dynamics of a healthy heartbeat is variable. Thus, complexity and cardiovascular dynamics are inversely related because they represent less interaction between the ANS regulatory mechanisms (24). In the present study, we observed that adults with SCA had lower ApEn than control adults. In line with our results, data from the literature show that patients with cardiovascular diseases have reduced ANS complexity than healthy individuals, and the reduction in ApEn is an independent predictor of total mortality (26). Given the role of the ANS in people with SCA, it is interesting to assess HRV following the different treatment modalities, including hydroxyurea therapy, blood transfusion and hematopoietic stem cell transplant (27). In this scenario, hydroxyurea therapy for people with SCA reduces the incidence of sudden cardiac death possibly associated with low HRV (28). Using cardiopulmonary exercise testing, a study showed that individuals with SCA on hydroxyurea therapy have heart rate recovery values closer to those seen in healthy controls (29). Considering the potential of HRV analysis during GA-T, we believe that prospective randomized studies are needed to assess ANS changes in response to the treatment of subjects with SCA.

Several things contribute to the poor performance of individuals with SCA during exercise, such as low oxygen-carrying ability of hemoglobin, cardiopulmonary

**Table 2.** Glittre ADL Test and Heart Rate Variability Data of Patients and Healthy Controls<sup>a</sup>

Variables	Sickle Cell Anemia Group (n = 16)	Control Healthy Group (n = 12)	P Value
<b>GA-T</b>			
Total time, s	257 (198 - 368)	179 (156 - 195)	0.007
<b>Heart rate variability</b>			
Maximum HR, bpm	141 (130 - 166)	130 (126 - 135)	0.025
Mean iRR, ms	499 (426 - 526)	610 (450 - 765)	0.020
SDNN, ms	18 (10 - 23)	26 (12 - 40)	0.033
RMSSD, ms	16 (10 - 19)	44 (37 - 52)	< 0.0001
pNN50, %	1.03 (0.35 - 2.53)	15.9 (12.5 - 22)	< 0.0001
TINN, ms	124 (100 - 166)	172 (128 - 203)	0.031
TP, ms <sup>2</sup>	448 (359 - 550)	762 (421 - 1365)	0.008
LF, ms <sup>2</sup>	80 (20 - 96)	117 (50 - 168)	0.014
LF, nu	83 (69 - 87)	94 (83 - 113)	0.020
HF, ms <sup>2</sup>	24 (12 - 44)	295 (199 - 326)	< 0.0001
HF, nu	15 (12 - 20)	37 (20 - 52)	0.003
LF/HF	1.96 (1.40 - 3.69)	0.91 (0.69 - 1)	< 0.0001
SD1, ms	8.20 (6.20 - 12.9)	36 (28 - 43)	< 0.0001
SD2, ms	26 (13 - 30)	50 (17 - 61)	0.013
SD2/SD1	2.64 (2 - 3.42)	2.51 (1.80 - 3.32)	0.68
ApEn	0.72 (0.57 - 0.92)	1.33 (1.26 - 1.52)	< 0.0001

Abbreviations: HR, heart rate; iRR; R-R intervals; SDNN, standard deviation of all normal iRR; RMSSD, root-mean-square difference of successive normal iRRs; pNN50, percentage of pairs of consecutive iRRs whose difference is > 50 m; TINN, triangular interpolation of iRR histogram; TP, total power; LF, low frequency in heart rate variability; HF, high frequency in heart rate variability; SD1, standard deviation of instantaneous beat-to-beat variability; SD2, standard deviation of long-term continuous iRRs; ApEn, approximate entropy.

<sup>a</sup> Values expressed as median and interquartile interval values.

changes, muscle dysfunction, osteoarticular lesions, and poor physical fitness (30). Compared to healthy controls, adults with SCA required a median of almost 50% more time to perform the GA-T tasks. We also noted that the longer the GA-T time was, the lower the HRV was, and PNS activity was especially low. Similar to our findings, Hedreville et al. (8) observed that the PNS activity indices were lower in patients with SCA than in healthy controls when these individuals were subjected to moderate acute exercise. Interestingly, we also observed a significant correlation between longer GA-T time and lower DLCO, which is in agreement with other authors who studied functional exercise capacity in adults with SCA (30). This finding reinforces the use of reduced DLCO as a marker of poor performance during exercise in individuals with SCA. It is also worth noting the relationships observed between the GA-T time and the PMF measures in our study, which indicate that the microvascular obstruction and the oxidative stress characteristic of SCA can negatively impact the peripheral muscles and reduce the performance of individu-

als during exercise (31-33).

A relationship between ANS behavior and pulmonary function has been discussed under both normal and pathological conditions (32-35). It has been hypothesized that HRV may be influenced by pulmonary function, regardless of cardiac autonomic control, with an increasing-decreasing HR resulting from a biphasic vagal response during the respiratory cycle that leads to instantaneous fluctuations in HRV-the so-called "respiratory sinus arrhythmia" (29, 35). To the best of our knowledge, no previously published work has analyzed the relationship between HRV and pulmonary function in individuals with SCA. Among the pulmonary function indices, we observed more significant correlations between DLCO and vagal modulation parameters. These findings are in line with those observed by Pitocco et al. (32) in individuals with type 1 diabetes, where they found a close relationship between ANS dysfunction and DLCO measures. It is hypothesized that ANS imbalance may modify the functioning of the peripheral and coronary microvasculature and play a

**Table 3.** Spearman's Correlation Coefficients between Heart Rate Variability, Glittere ADL Test, Pulmonary Function, and Peripheral Muscle Strength

Variables	GA-T time	FVC	DLco	PImax	PEmax	HGS	QS
Maximum HR, bpm	0.100	-0.171	-0.303	0.113	-0.006	-0.215	-0.192
Mean iRR, ms	-0.274	0.229	0.477	0.118	0.105	0.339	0.336
SDNN, ms	-0.535 <sup>a, b</sup>	0.435	0.381	0.537 <sup>a, b</sup>	0.115	0.327	0.376
RMSSD, ms	-0.650 <sup>a, c</sup>	0.271	0.605 <sup>a, b</sup>	0.620 <sup>a, c</sup>	0.302	0.503 <sup>a, b</sup>	0.508 <sup>a, b</sup>
pNN50, %	-0.932 <sup>a, d</sup>	0.188	0.578 <sup>a, b</sup>	0.733 <sup>a, d</sup>	0.245	0.501 <sup>a, b</sup>	0.538 <sup>a, b</sup>
TINN, ms	-0.526 <sup>a, b</sup>	0.186	0.383	0.627 <sup>a, c</sup>	0.075	0.120	0.191
Total power, ms <sup>2</sup>	-0.529 <sup>a, b</sup>	0.100	0.472	0.489	-0.058	0.130	0.180
LF, ms <sup>2</sup>	-0.074	0.415	0.277	0.258	0.128	-0.007	-0.085
LF, nu	0.312	0.356	0.097	-0.149	-0.022	0.050	0.038
HF, ms <sup>2</sup>	-0.579 <sup>a, b</sup>	0.138	0.518 <sup>a, b</sup>	0.396	-0.010	0.224	0.299
HF, nu	0.209	-0.274	-0.439	0.003	-0.058	-0.352	-0.432
LF/HF	0.318	0.544 <sup>a, b</sup>	0.034	-0.121	0.494	0.016	-0.171
SD1, ms	-0.814 <sup>a, d</sup>	0.229	0.602 <sup>a, b</sup>	0.745 <sup>a, c</sup>	0.361	0.496 <sup>a, b</sup>	0.500 <sup>a, b</sup>
SD2, ms	-0.480	0.406	0.460	0.489	0.087	0.292	0.343
SD2/SD1	0.215	0.397	0.184	-0.141	-0.173	-0.088	-0.093
ApEn	-0.653 <sup>a, c</sup>	-0.091	-0.284	-0.364	-0.046	-0.337	-0.436

Abbreviations: GA-T, Glittere ADL test; FVC, forced vital capacity; DLco, diffusing capacity for carbon monoxide; PImax, maximal inspiratory pressure, PEmax, maximal expiratory pressure; HGS, handgrip strength; QS, quadriceps strength; HR, heart rate; iRR, R-R intervals; SDNN, standard deviation of all normal iRR; RMSSD, root-mean-square difference of successive normal iRRs; pNN50, percentage of pairs of consecutive iRRs whose difference is > 50 ms; TINN, triangular interpolation of iRR histogram; TP, total power; LF, low frequency in heart rate variability; HF, high frequency in heart rate variability; SD1, standard deviation of instantaneous beat-to-beat variability; SD2, standard deviation of long-term continuous iRRs; ApEn, approximate entropy.

<sup>a</sup> Bold type indicates significant correlations.

<sup>b</sup>  $p < 0.05$ .

<sup>c</sup>  $p < 0.01$ .


<sup>d</sup>  $p < 0.0001$ .

role in abnormal regulation of pulmonary microcirculation (33). Thus, we hypothesized that ANS dysfunction is involved in the early reduction in DLCO in people with SCA, possibly due to abnormal blood flow regulation at the pulmonary microvascular level. We also observed a significant relationship between HRV indices (especially those that reflect PNS activity) and PImax. In this sense, it is important to note that the vagus, in addition to being involved in the innervation of the heart's PNS, also plays a role in the innervation of the respiratory muscles; therefore, there is some level of synchronicity between the activities of the respiratory and heart muscles (33).

Autonomic neuropathy may contribute to the pathogenesis of muscle dysfunction in various clinical conditions, with different degrees of impairment of the baroreflex mechanism of skeletal muscle. Here, the lower the HRV (especially the lower the PNS activity) the lower the PMF, as observed by Kabbach et al. (24), Camillo et al. (36), and de Lima et al. (37) in other patient populations, such as patients with chronic obstructive pulmonary disease or terminal liver disease. The relationship between HRV and

PMF may have important implications. HGS has been described as a marker of the both regional (upper limbs) and integrity of global function of the individual, whereas an adequate HRV seems to reflect a healthy status with a self-regulated and adaptable cardiovascular system. In addition, HGS has been reported to be negatively associated with all-cause mortality (38). Therefore, an understanding of the relationships between HRV and PMF can help to determine whether HRV is associated with various aspects of SCA, thereby enabling the proposal of intervention strategies that can influence the results.

A major contribution of this study comprises the first evaluation of the phenotype of HRV in adults with SCA as compared to a control group during a submaximal test with multitasking that mimics ADLs. However, we must recognize its main limitations. First, the study population size was small, although the most significant correlations were almost always observed for the same parameters (i.e., PNS modulation indices). Second, we only evaluated adults with SCA, which prevents the generalization of our results to younger age groups of patients with the disease. Finally,



**Figure 2.** Relationships of the Glittre ADL test (GA-T) time with the root-mean-square difference of successive normal iRR (RMSSD,  $r_s = -0.650$ ,  $P < 0.01$ ), A, the percent of iRR differing by  $>50$  ms from the preceding one (pNN50,  $r_s = -0.932$ ,  $P < 0.0001$ ); B, the high frequency in heart rate variability (HF,  $r_s = -0.579$ ,  $P < 0.01$ ); C, and the standard deviation measuring the dispersion of points in the plot perpendicular to the line of identity (SD1,  $r_s = -0.814$ ,  $P < 0.0001$ ); D, in sickle cell anemia (SCA) individuals.

the lack of normative values for HRV parameters during the GA-T makes it difficult to establish cutoff points for abnormal HRV in the participants, although we used a control group. However, this study can serve as a theoretical reference for the design of other research aimed at evaluating intervention strategies that consider the ANS during submaximal exercise in patients with SCA. It is also worth noting that the relationships between HRV abnormalities, pulmonary dysfunction, and muscle dysfunction may also contribute to the future research in these individuals.

### 5.1. Conclusions

Adults with SCA have reduced HRV, and their low PNS activity, sympathovagal imbalance, and the abnormal complexity of the ANS are particularly important. In addition, a lower HRV is associated with a longer time to complete the GA-T, greater impairment in lung diffusion, and greater dysfunction of both respiratory muscle strength and peripheral muscle strength. Thus, the evaluation of HRV during GA-T may be worthwhile for the follow-up of

individuals with SCA, including in the evaluation of their response to treatment.

### Footnotes

**Authors' Contribution:** Study concept and design, Rafael Alexandre de Oliveira Deucher, Leila Paula Alves da Silva Nascimento, and Agnaldo José Lopes; Analysis and interpretation of data, Rafael Alexandre de Oliveira Deucher, Arthur de Sá Ferreira, Leila Paula Alves da Silva Nascimento, Mariana Soares da Cal, and Agnaldo José Lopes; Drafting of the manuscript, Rafael Alexandre de Oliveira Deucher, Arthur de Sá Ferreira, Leila Paula Alves da Silva Nascimento, Mariana Soares da Cal, Jannis Vasileios Papathanasiou, and Agnaldo José Lopes; Critical revision of the manuscript for important intellectual content, Rafael Alexandre de Oliveira Deucher, Arthur de Sá Ferreira, Leila Paula Alves da Silva Nascimento, Mariana Soares da Cal, Jannis Vasileios Papathanasiou, and Agnaldo José Lopes; Statistical analysis, Arthur de Sá Ferreira and Agnaldo José Lopes.



**Conflict of Interests:** The authors declare that they have no conflict of interest.

**Ethical Approval:** The Research Ethics Committee of the State University of Rio de Janeiro approved this study protocol (No. 1.718.917/2016).

**Funding/Support:** This research was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq: 407138/2018-8 and 302215/2019-0), the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES: Finance code 001), and the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ: #E-26/202.679/2018 and #E-26/010.002124/2019).

**Informed Consent:** All participants signed a written informed consent form.

## References

- Carden MA, Little J. Emerging disease-modifying therapies for sickle cell disease. *Haematologica*. 2019;**104**(9):1710–9. doi: [10.3324/haematol.2018.207357](https://doi.org/10.3324/haematol.2018.207357). [PubMed: [3143089](https://pubmed.ncbi.nlm.nih.gov/3143089/)]. [PubMed Central: [PMC6717563](https://pubmed.ncbi.nlm.nih.gov/PMC6717563/)].
- Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. *Lancet*. 2010;**376**(9757):2018–31. doi: [10.1016/S0140-6736\(10\)61029-X](https://doi.org/10.1016/S0140-6736(10)61029-X). [PubMed: [21131035](https://pubmed.ncbi.nlm.nih.gov/21131035/)].
- Chalacheva P, Kato RM, Shah P, Veluswamy S, Denton CC, Sunwoo J, et al. Sickle cell disease subjects have a distinct abnormal autonomic phenotype characterized by peripheral vasoconstriction with blunted cardiac response to head-up tilt. *Front Physiol*. 2019;**10**:381. doi: [10.3389/fphys.2019.00381](https://doi.org/10.3389/fphys.2019.00381). [PubMed: [31031633](https://pubmed.ncbi.nlm.nih.gov/31031633/)]. [PubMed Central: [PMC6470196](https://pubmed.ncbi.nlm.nih.gov/PMC6470196/)].
- Adebiji AA, Oyebowale OM, Olaniyi AJ, Falase AO. Heart rate variability study in adult Nigerian subjects with sickle cell disease during vaso-occlusive crisis. *Niger Postgrad Med J*. 2019;**26**(1):8–12. doi: [10.4103/npmj.npmj\\_186\\_18](https://doi.org/10.4103/npmj.npmj_186_18). [PubMed: [30860193](https://pubmed.ncbi.nlm.nih.gov/30860193/)].
- Kolo PM, Sanya EO, Olanrewaju TO, Fawibe AE, Soladoye A. Cardiac autonomic dysfunction in sickle cell anaemia and its correlation with QT parameters. *Niger Med J*. 2013;**54**(6):382–5. doi: [10.4103/0300-1652.126288](https://doi.org/10.4103/0300-1652.126288). [PubMed: [24665151](https://pubmed.ncbi.nlm.nih.gov/24665151/)]. [PubMed Central: [PMC3948959](https://pubmed.ncbi.nlm.nih.gov/PMC3948959/)].
- Sangkatumvong S, Coates TD, Khoo MC. Abnormal autonomic cardiac response to transient hypoxia in sickle cell anemia. *Physiol Meas*. 2008;**29**(5):655–68. doi: [10.1088/0967-3334/29/5/010](https://doi.org/10.1088/0967-3334/29/5/010). [PubMed: [18460753](https://pubmed.ncbi.nlm.nih.gov/18460753/)]. [PubMed Central: [PMC2956125](https://pubmed.ncbi.nlm.nih.gov/PMC2956125/)].
- Oguanobi NI, Onwubere BJ, Anisiuba BC, Ike SO, Ejim EC, Ibegbulam OG. Clinical findings associated with cardiovascular autonomic dysfunction in adult sickle cell anaemia patients. *Acta Cardiol*. 2012;**67**(2):169–75. doi: [10.1080/ac.67.2.2154207](https://doi.org/10.1080/ac.67.2.2154207). [PubMed: [22641974](https://pubmed.ncbi.nlm.nih.gov/22641974/)].
- Hedreville M, Charlot K, Waltz X, Sinnaph S, Lemonne N, Etienne-Julan M, et al. Acute moderate exercise does not further alter the autonomic nervous system activity in patients with sickle cell anemia. *PLoS One*. 2014;**9**(4). e95563. doi: [10.1371/journal.pone.0095563](https://doi.org/10.1371/journal.pone.0095563). [PubMed: [24740295](https://pubmed.ncbi.nlm.nih.gov/24740295/)]. [PubMed Central: [PMC3989338](https://pubmed.ncbi.nlm.nih.gov/PMC3989338/)].
- Charlot K, Moeckesch B, Jument S, Romana M, Waltz X, Divialle-Doumdo L, et al. Physical activity level is not a determinant of autonomic nervous system activity and clinical severity in children/adolescents with sickle cell anemia: A pilot study. *Pediatr Blood Cancer*. 2015;**62**(11):1962–7. doi: [10.1002/pbc.25604](https://doi.org/10.1002/pbc.25604). [PubMed: [25989908](https://pubmed.ncbi.nlm.nih.gov/25989908/)].
- Skumlien S, Hagelund T, Bjortuft O, Ryg MS. A field test of functional status as performance of activities of daily living in COPD patients. *Respir Med*. 2006;**100**(2):316–23. doi: [10.1016/j.rmed.2005.04.022](https://doi.org/10.1016/j.rmed.2005.04.022). [PubMed: [15941658](https://pubmed.ncbi.nlm.nih.gov/15941658/)].
- Reis CMD, Karloh M, Fonseca FR, Biscaro RRM, Mazo GZ, Mayer AF. Functional capacity measurement: Reference equations for the glittre activities of daily living test. *J Bras Pneumol*. 2018;**44**(5):370–7. doi: [10.1590/S1806-37562017000000118](https://doi.org/10.1590/S1806-37562017000000118). [PubMed: [30020345](https://pubmed.ncbi.nlm.nih.gov/30020345/)]. [PubMed Central: [PMC6467592](https://pubmed.ncbi.nlm.nih.gov/PMC6467592/)].
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J*. 2005;**26**(2):319–38. doi: [10.1183/09031936.05.00034805](https://doi.org/10.1183/09031936.05.00034805). [PubMed: [16055882](https://pubmed.ncbi.nlm.nih.gov/16055882/)].
- Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, et al. Recommendations for a standardized pulmonary function report. An official american thoracic society technical statement. *Am J Respir Crit Care Med*. 2017;**196**(11):1463–72. doi: [10.1164/rccm.201710-1981ST](https://doi.org/10.1164/rccm.201710-1981ST). [PubMed: [29192835](https://pubmed.ncbi.nlm.nih.gov/29192835/)].
- Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005;**26**(5):948–68. doi: [10.1183/09031936.05.00035205](https://doi.org/10.1183/09031936.05.00035205). [PubMed: [16264058](https://pubmed.ncbi.nlm.nih.gov/16264058/)].
- Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. *J Bras Pneumol*. 2007;**33**(4):397–406. doi: [10.1590/s1806-37132007000400008](https://doi.org/10.1590/s1806-37132007000400008). [PubMed: [17982531](https://pubmed.ncbi.nlm.nih.gov/17982531/)].
- Neder JA, Andreoni S, Peres C, Nery LE. Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). *Braz J Med Biol Res*. 1999;**32**(6):729–37. doi: [10.1590/s0100-879x1999000600008](https://doi.org/10.1590/s0100-879x1999000600008). [PubMed: [10412551](https://pubmed.ncbi.nlm.nih.gov/10412551/)].
- Neder JA, Andreoni S, Lerario MC, Nery LE. Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. *Braz J Med Biol Res*. 1999;**32**(6):719–27. doi: [10.1590/s0100-879x1999000600007](https://doi.org/10.1590/s0100-879x1999000600007). [PubMed: [10412550](https://pubmed.ncbi.nlm.nih.gov/10412550/)].
- Crosby CA, Wehbe MA, Mawr B. Hand strength: Normative values. *J Hand Surg Am*. 1994;**19**(4):665–70. doi: [10.1016/0363-5023\(94\)90280-1](https://doi.org/10.1016/0363-5023(94)90280-1). [PubMed: [7963331](https://pubmed.ncbi.nlm.nih.gov/7963331/)].
- de Andrade Junior AB, Ferreira A, Assis ACB, Nascimento L, Ribeiro CF, Papathanasiou JV, et al. Cardiac autonomic control in women with rheumatoid arthritis during the glittre activities of daily living test. *Asian J Sports Med*. 2020;**11**(2). doi: [10.5812/asjasm.101400](https://doi.org/10.5812/asjasm.101400).
- Cunha FA, Montenegro RA, Midgley AW, Vasconcelos F, Soares PP, Farinatti P. Influence of exercise modality on agreement between gas exchange and heart rate variability thresholds. *Braz J Med Biol Res*. 2014;**47**(8):706–14. doi: [10.1590/j1414-431x20143713](https://doi.org/10.1590/j1414-431x20143713). [PubMed: [25003546](https://pubmed.ncbi.nlm.nih.gov/25003546/)]. [PubMed Central: [PMC4165298](https://pubmed.ncbi.nlm.nih.gov/PMC4165298/)].
- Correa PR, Catai AM, Takakura IT, Machado MN, Godoy MF. [Heart rate variability and pulmonary infections after myocardial revascularization]. *Arq Bras Cardiol*. 2010;**95**(4):448–56. Spanish. doi: [10.1590/s0066-782x2010005000123](https://doi.org/10.1590/s0066-782x2010005000123). [PubMed: [20835682](https://pubmed.ncbi.nlm.nih.gov/20835682/)].
- No Authors Listed. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Eur Heart J*. 1996;**17**(3):354–81. [PubMed: [8737210](https://pubmed.ncbi.nlm.nih.gov/8737210/)].
- Charlot K, Hierso R, Lemonne N, Romana M, Tressieres B, Lalanne-Mistrih ML, et al. Changes in autonomic nervous activity during vaso-occlusive crisis in patients with sickle cell anaemia. *Br J Haematol*. 2017;**177**(3):484–6. doi: [10.1111/bjh.14064](https://doi.org/10.1111/bjh.14064). [PubMed: [27009926](https://pubmed.ncbi.nlm.nih.gov/27009926/)].
- Kabbach EZ, Mazzuco A, Borghi-Silva A, Cabiddu R, Agnoletto AG, Barbosa JF, et al. Increased parasympathetic cardiac modulation in patients with acute exacerbation of COPD: How should we interpret it? *Int J Chron Obstruct Pulmon Dis*. 2017;**12**:2221–30. doi: [10.2147/COPD.S134498](https://doi.org/10.2147/COPD.S134498). [PubMed: [28814850](https://pubmed.ncbi.nlm.nih.gov/28814850/)]. [PubMed Central: [PMC5546179](https://pubmed.ncbi.nlm.nih.gov/PMC5546179/)].

25. Ai J, Epstein PN, Gozal D, Yang B, Wurster R, Cheng ZJ. Morphology and topography of nucleus ambiguus projections to cardiac ganglia in rats and mice. *Neuroscience*. 2007;**149**(4):845–60. doi: [10.1016/j.neuroscience.2007.07.062](https://doi.org/10.1016/j.neuroscience.2007.07.062). [PubMed: [17942236](https://pubmed.ncbi.nlm.nih.gov/17942236/)].
26. Cygankiewicz I, Corino V, Vazquez R, Bayes-Genis A, Mainardi L, Zareba W, et al. Reduced irregularity of ventricular response during atrial fibrillation and long-term outcome in patients with heart failure. *Am J Cardiol*. 2015;**116**(7):1071–5. doi: [10.1016/j.amjcard.2015.06.043](https://doi.org/10.1016/j.amjcard.2015.06.043). [PubMed: [26298305](https://pubmed.ncbi.nlm.nih.gov/26298305/)].
27. Meier ER. Treatment options for sickle cell disease. *Pediatr Clin North Am*. 2018;**65**(3):427–43. doi: [10.1016/j.pcl.2018.01.005](https://doi.org/10.1016/j.pcl.2018.01.005). [PubMed: [29803275](https://pubmed.ncbi.nlm.nih.gov/29803275/)].
28. Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, et al. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. *N Engl J Med*. 2019;**380**(2):121–31. doi: [10.1056/NEJMoa1813598](https://doi.org/10.1056/NEJMoa1813598). [PubMed: [30501550](https://pubmed.ncbi.nlm.nih.gov/30501550/)]. [PubMed Central: [PMC6454575](https://pubmed.ncbi.nlm.nih.gov/PMC6454575/)].
29. Alvarado AM, Ward KM, Muntz DS, Thompson AA, Rodeghier M, Fernhall B, et al. Heart rate recovery is impaired after maximal exercise testing in children with sickle cell anemia. *J Pediatr*. 2015;**166**(2):389–93. doi: [10.1016/j.jpeds.2014.10.064](https://doi.org/10.1016/j.jpeds.2014.10.064). [PubMed: [25477159](https://pubmed.ncbi.nlm.nih.gov/25477159/)]. [PubMed Central: [PMC4308440](https://pubmed.ncbi.nlm.nih.gov/PMC4308440/)].
30. Marinho CL, Maioli MC, Soares AR, Bedirian R, Melo PL, Guimaraes FS, et al. Predictive models of six-minute walking distance in adults with sickle cell anemia: Implications for rehabilitation. *J Bodyw Mov Ther*. 2016;**20**(4):824–31. doi: [10.1016/j.jbmt.2016.02.005](https://doi.org/10.1016/j.jbmt.2016.02.005). [PubMed: [27814863](https://pubmed.ncbi.nlm.nih.gov/27814863/)].
31. Goncalves CEA, Silva PO, Soares MS, Bunn PS, Lima CMA, Lopes AJ. Muscle dysfunction is associated with poorer health-related quality of life in adults with sickle cell anaemia. *J Back Musculoskelet Rehabil*. 2019;**32**(1):43–53. doi: [10.3233/BMR-171027](https://doi.org/10.3233/BMR-171027). [PubMed: [30056413](https://pubmed.ncbi.nlm.nih.gov/30056413/)].
32. Pitocco D, Santangeli P, Fuso L, Zaccardi F, Longobardi A, Infusino F, et al. Association between reduced pulmonary diffusing capacity and cardiac autonomic dysfunction in Type 1 diabetes. *Diabet Med*. 2008;**25**(11):1366–9. doi: [10.1111/j.1464-5491.2008.02571.x](https://doi.org/10.1111/j.1464-5491.2008.02571.x). [PubMed: [19046231](https://pubmed.ncbi.nlm.nih.gov/19046231/)].
33. Durdik P, Vojtkova J, Michnova Z, Turcan T, Sujanska A, Kuchta M, et al. Pulmonary function tests in type 1 diabetes adolescents with diabetic cardiovascular autonomic neuropathy. *J Diabetes Complications*. 2016;**30**(1):79–84. doi: [10.1016/j.jdiacomp.2015.10.011](https://doi.org/10.1016/j.jdiacomp.2015.10.011). [PubMed: [26597599](https://pubmed.ncbi.nlm.nih.gov/26597599/)].
34. Sant' Anna M, Carvalhal RF, Carneiro JR, Lapa MS, Zin WA, Lugon JR, et al. Association between respiratory mechanics and autonomic function in morbid obesity. *Rev Port Pneumol*. 2014;**20**(1):31–5. doi: [10.1016/j.rppneu.2013.06.009](https://doi.org/10.1016/j.rppneu.2013.06.009). [PubMed: [24315398](https://pubmed.ncbi.nlm.nih.gov/24315398/)].
35. Bianchim MS, Sperandio EF, Martinhao GS, Matheus AC, Lauria VT, da Silva RP, et al. Correlation between heart rate variability and pulmonary function adjusted by confounding factors in healthy adults. *Braz J Med Biol Res*. 2016;**49**(3). doi: [10.1590/1414-431X20154435](https://doi.org/10.1590/1414-431X20154435). [PubMed: [26840706](https://pubmed.ncbi.nlm.nih.gov/26840706/)]. [PubMed Central: [PMC4763812](https://pubmed.ncbi.nlm.nih.gov/PMC4763812/)].
36. Camillo CA, Pitta F, Possani HV, Barbosa MV, Marques DS, Cavalheri V, et al. Heart rate variability and disease characteristics in patients with COPD. *Lung*. 2008;**186**(6):393–401. doi: [10.1007/s00408-008-9105-7](https://doi.org/10.1007/s00408-008-9105-7). [PubMed: [18815834](https://pubmed.ncbi.nlm.nih.gov/18815834/)].
37. de Lima DC, Ribeiro HS, Cristina R, Oliveira M, Generoso Sde V, Lima AS, et al. Functional status and heart rate variability in end-stage liver disease patients: association with nutritional status. *Nutrition*. 2015;**31**(7–8):971–4. doi: [10.1016/j.nut.2015.01.014](https://doi.org/10.1016/j.nut.2015.01.014). [PubMed: [26059370](https://pubmed.ncbi.nlm.nih.gov/26059370/)].
38. Koopman FA, Tang MW, Vermeij J, de Hair MJ, Choi IY, Vervoordeldonk MJ, et al. Autonomic dysfunction precedes development of rheumatoid arthritis: A prospective Cohort study. *EBioMedicine*. 2016;**6**:231–7. doi: [10.1016/j.ebiom.2016.02.029](https://doi.org/10.1016/j.ebiom.2016.02.029). [PubMed: [27211565](https://pubmed.ncbi.nlm.nih.gov/27211565/)]. [PubMed Central: [PMC4856742](https://pubmed.ncbi.nlm.nih.gov/PMC4856742/)].